analysis for NCT00251719 [clinicaltrials_resource:NCT00251719/analysis/2575f5a7829d6d49b8f27651b9d4eee6]
analysis [clinicaltrials_vocabulary:analysis]
analysis for NCT00251719 [clinicaltrials_resource:NCT00251719/analysis/2575f5a7829d6d49b8f27651b9d4eee6]
Bio2RDF identifier
NCT00251719/analysis/2575f5a7829d6d49b8f27651b9d4eee6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 75f5a7829d6d49b8f27651b9d4eee6
method [clinicaltrials_vocabulary:method]
Cochran-Mantel-Haenszel
non inferiority [clinicaltrials_vocabulary:non-inferiority]
p value [clinicaltrials_vocabulary:p-value]
6.400000303983688e-2
p value desc [clinicaltrials_vocabulary:p-value-desc]
Unadjusted p-value is presente ...... oprazole dose to lansoprazole.
identifier
clinicaltrials_resource:NCT00251719/analysis/2575f5a7829d6d49b8f27651b9d4eee6
title
analysis for NCT00251719
@en
type
label
analysis for NCT00251719 [clin ...... 5f5a7829d6d49b8f27651b9d4eee6]
@en